Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1985 1
2000 2
2005 2
2009 1
2010 1
2011 1
2012 2
2013 1
2019 1
2021 1
2022 4
2023 6
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.
Bakker WM, Heerspink HJL, Berger SP, Wanner C, Badve SV, Arnott C, Abrahams AC, van den Born JC, van Faassen TC, Gaillard CAJM, Gelens MACJ, Górris JL, Hemmelder MH, Jakulj L, van Kruijsdijk RCM, Kuypers DRJ, van der Meer P, van der Net JB, Nijmeijer HH, Vervloet MG, de Vries APJ, Walsh M, Wang AY, Gansevoort RT; Renal Lifecycle Trial Investigators. Bakker WM, et al. Nephrol Dial Transplant. 2025 Aug 29;40(9):1746-1755. doi: 10.1093/ndt/gfaf046. Nephrol Dial Transplant. 2025. PMID: 40053493 Free PMC article.
Hyperhomocysteinemia: a trigger for complement-mediated TMA?
Bernards J, Doubel P, Meeus G, Lerut E, Corveleyn A, Van Den Heuvel LP, Meersseman W, Kuypers DK, Claes KJ. Bernards J, et al. Acta Clin Belg. 2021 Feb;76(1):65-69. doi: 10.1080/17843286.2019.1649039. Epub 2019 Aug 11. Acta Clin Belg. 2021. PMID: 31401947
Addressing the inequity of access to home Dialysis in Europe: recommendations for action informed by an international consensus exercise.
Davies SJ, Bammens B, de Barbieri I, Brown EA, van Cruchten J, Gallego D, Goffin E, Gallieni M, Gliki S, Kooman JP, Meeus G, Moeslund-Hansen MB, Rutherford P, Vanholder R, Wilkie M, Van Biesen W. Davies SJ, et al. BMC Nephrol. 2025 Jun 3;26(1):276. doi: 10.1186/s12882-025-04188-y. BMC Nephrol. 2025. PMID: 40461978 Free PMC article.
Clinicopathological characteristics and disease chronicity in native kidney biopsies in Flanders.
Deleersnijder D, Laurens W, De Meester J, Cleenders E, Dendooven A, Lerut E, De Vriese AS, Dejagere T, Helbert M, Hellemans R, Koshy P, Maes B, Pipeleers L, Van Craenenbroeck AH, Van Laecke S, Vande Walle J, Couttenye MM, Meeus G, Sprangers B; FCGG collaborative group. Deleersnijder D, et al. Clin Kidney J. 2022 Sep 14;16(1):125-137. doi: 10.1093/ckj/sfac208. eCollection 2023 Jan. Clin Kidney J. 2022. PMID: 36726429 Free PMC article.
Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study.
Robella M, Hubner M, Sgarbura O, Reymond M, Khomiakov V, di Giorgio A, Bhatt A, Bakrin N, Willaert W, Alyami M, Teixeira H, Kaprin A, Ferracci F, De Meeus G, Berchialla P, Vaira M; ISSPP PIPAC study group. Robella M, et al. Eur J Surg Oncol. 2022 Oct;48(10):2212-2217. doi: 10.1016/j.ejso.2022.05.001. Epub 2022 May 7. Eur J Surg Oncol. 2022. PMID: 35577665
24 results